Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death
04/06/2026 12:07
BRIEF-Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death June 4 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O:
LUPKYNIS ASSOCIATED WITH A STATISTICALLY SIGNIFICANT 53% REDUCTION IN RISK OF RENAL-RELATED EVENT OR DEATH
Source text: ID:nBw2PGlh3a
Further company coverage: AUPH.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death